<p>Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma</p>

• DOI: 10.2147/cmar.s192868
• Publication Date: 2019-04-22T18:34:11Z
• Authors: Yuan Li; Pan Huang; Hongju Peng; Hongcheng Yue; Min Wu; Shanshan Liu; Rongsheng Qin; Juan Fan; Yunwei Han
• Keywords: Endostatin; Lewis lung carcinoma

Background: Endostatin therapy is known to efficiently inhibit angiogenesis and growth of endothelial cells. Nonetheless, the antitumor mechanisms endostatin combined with chemotherapy remain be elucidated. Methods: In our study, a Lewis lung carcinoma transplant mouse model was established treated recombinant human [rh]-endostatin, Endostar, gemcitabine at different sequences. 18F-FDG PET/CT imaging performed monitor tumor growth, hypoxia examined using an oxygen microelectrode. Vascular factor (VEGF) alpha smooth muscle actin (α-SMA) levels were detected via immunohistochemistry analysis cell cycle distributions analyzed by flow cytometry. Results: Endostar decreased VEGF expression, improved hypoxia, influenced distributions. Simultaneous treatment displayed significantly inhibition, possessed lowest uptake FDG, partial pressure, expression VEGF, increased pericyte coverage. Cell demonstrated that cells accumulated in S phase following G0/G1 arrest occurred treatment. An increase observed gemcitabine. Conclusions: Our study suggests combination simutaneously may optimally enhance their individual effects. Keywords: endostatin, gemcitabine, antiangiogenic,